AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

OPKO Health Inc.

Director's Dealing Nov 19, 2025

6963_rns_2025-11-19_8736004b-9c54-4307-b6d9-0284a7332b41.pdf

Director's Dealing

Open in Viewer

Opens in native device viewer

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Instruction 10. (Print or Type Responses)

1. Name and Address of Reporting Person *
Phillip Frost, M.D., ET AL
2. Issuer Name and Ticker or Trading Symbol
OPKO Health, Inc. [ OPK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
(Last)
OPKO Health, Inc.
4400 Biscayne Blvd.
(First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025
X Director
X 10% Owner
X Officer (give title below)
Other (specify below)
CEO & Chairman
Miami, FL 33137 (Street) 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person
(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security
(Instr. 3)
2. Transaction
Date (Month
/Day/Year)
2A. Deemed
Execution
Date, if any
3. Transaction
Code
(Instr. 8)
4. Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned
Following Reported Transaction(s)
(Instr. 3 and 4)
6.
Ownership
Form:
7. Nature
of Indirect
Beneficial
(Month/Day
/Year)
Code V Amount (A) or
(D)
Price Direct (D)
or Indirect
(I)
(Instr. 4)
Ownership
(Instr. 4)
Common Stock 11/18/2025 P 410 A \$ 1.245 214,386,858 I See
Footnote
(1)
Common Stock 11/18/2025 P 49,590 A \$ 1.25 214,436,448 I See
Footnote
(1)
Common Stock 11/18/2025 P 66,635 A \$ 1.255 214,503,083 I See
Footnote
(1)
Common Stock 11/18/2025 A 46,700 A \$ 1.26 214,549,783 I See
Footnote
(1)
Common Stock 11/18/2025 P 15,000 A \$ 1.265 214,564,783 I See
Footnote
(1)
Common Stock 11/18/2025 P 1,772 A \$ 1.27 214,566,555 I See
Footnote
(1)
Common Stock 11/18/2025 P 212,608 A \$ 1.275 214,779,163 I See
Footnote
(1)
Common Stock 11/18/2025 P 69,728 A \$ 1.28 214,848,891 I See
Footnote
(1)
Common Stock 11/18/2025 P 428 A \$ 1.2847 214,849,319 I See
Footnote
(1)
Common Stock 11/18/2025 P 83,556 A \$ 1.285 214,932,875 I See
Footnote
(1)
Common Stock 11/18/2025 P 1 A \$ 1.2859 214,932,876 I See
Footnote
(1)
Common Stock 11/18/2025 P 33,572 A \$ 1.29 214,966,448 I See
Footnote
(1)
Common Stock 3,568,951 D
Common Stock 30,127,177 I See
Footnote
(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative
Security
(Instr. 3)
2. Conversion
or Exercise
Price of
Derivative
Security
3. Transaction
Date (Month
/Day/Year)
3A. Deemed
Execution
Date, if any
(Month/Day
/Year)
4. Transaction
Code
(Instr. 8)
5. Number of
Derivative Securities
Acquired (A) or
Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration
Date
(Month/Day/Year)
7. Title and Amount of
Underlying Securities
(Instr. 3 and 4)
8. Price of
Derivative
Security
(Instr. 5)
9. Number
of
Derivative
Securities
Beneficially
10.
Ownership
Form of
Derivative
Security:
11. Nature
of Indirect
Beneficial
Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or
Number of Shares
Owned
Following
Reported
Transaction
(s)
(Instr. 4)
Direct (D)
or Indirect
(I)
(Instr. 4)
1. Name and Address of Reporting Person*
Phillip Frost, M.D., ET AL
(Last) OPKO Health, Inc.
4400 Biscayne Blvd.
(First) (Middle)
(Street)
Miami
FL 33137
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X
X
Director Officer (give title below)
CEO & Chairman
X 10% Owner
Other (specify below)
1. Name and Address of Reporting Person*
Frost Gamma Investments Trust
(Last) OPKO Health, Inc.
4400 Biscayne Blvd.
(First) (Middle)
(Street)
Miami
FL 33137
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director Officer (give title below) X 10% Owner
Other (specify below)

Explanation of Responses:

  • 1. The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  • 2. These securities are held by Frost Nevada Investments Trust, of which the Reporting Person is the trustee and Frost-Nevada, L.P. is the sole and exclusive beneficiary. The Reporting Person is one of seven limited partners of Frost-Nevada, L.P. and the sole shareholder of Frost-Nevada Corporation, the sole general partner of Frost-Nevada, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Phillip Frost, M.D., Individually and as Trustee 11/18/2025
**
Signature of Reporting Person
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  • ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

JOINT FILER INFORMATION

Name: Frost Gamma Investments Trust

Address:

4400 Biscayne Blvd. Miami, FL 33137

Designated Filer: Phillip Frost, M.D.

Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)

Date of Earliest Transaction: November 18, 2025

Relationship to Issuer: 10% Owner

FROST GAMMA INVESTMENTS TRUST

By: /s/ Phillip Frost, M.D., as Trustee Phillip Frost, M.D., Trustee

Talk to a Data Expert

Have a question? We'll get back to you promptly.